Summary of safety profile and future research with alendronate

British Journal of Rheumatology

Volumn 36, Issue SUPPL. 1, 1997, Pages 20-23

  Daifotis, A G ^a   Karpf, D B ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Alendronate; Bone quality; Histomorphometry; Side effects; Tolerability

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE;

ARTICLE; BONE MASS; BONE MINERALIZATION; BONE STRENGTH; CLINICAL TRIAL; DRUG RESEARCH; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; OSTEOLYSIS; OSTEOPOROSIS; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY;

EID: 0030816322     PISSN: 02637103     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (8)

1. Fleisch H. Bisphosphonates: pharmacology and use in treatment of tumor-induced hypercalcemic and metastatic bone disease. Drugs 1991;42:919-44.
2. Schenk R, Eggli P, Fleisch H, Rosini S. Quantitative morphometric evaluation of the inhibitory activity of new aminobisphosphonates on bone resorption in the rat. Calcif Tissue Int 1986;38:342-9.
3. Sato M, Grasser W, Endo N et al. Bisphosphonate action: alendronate localization in rat bone and effects on osteoclastultrastructure. J Clin Invest 1991;88:2095-105.
4. Liberman UA, Weiss SR, Broll J et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med 1995;333:1437-43.
5. Tukey JW, Ciminera JL, Heyse JF. The consultant's forum. Testing the statistical certainty of a response to increasing doses of a drug. Biometrics 1985;41:295-301.
6. Lufkin EG, Argueta R, Whitaker MD et al. Pamidronate: an unrecognized problem in gastrointestinal tolerability. Osteopor Int 1994;4:320-2.
7. Schiller JH, Rasmussen P, Benson AB III et al. Maintenance etidronate in the prevention of malignancy-associated hypercalcemia. Arch Intern Med 1987;147: 963-6.
8. Black DM, Reiss TF, Nevitt MC et al. Design of the Fracture Intervention Trial. Osteopor Int 1993;suppl 3: S29-39.